English 
Nxera Pharma has launched a wide range of unique treatments. These aim to create next-generation therapies for obesity and related metabolic issues. The company is moving forward with its own drug discovery. This is true even with its partnerships with Pfizer and Eli Lilly. It is focusing on several proven G protein-coupled receptor (GPCR) targets.
The new pipeline features an oral small molecule GLP-1 agonist. This drug is fully owned and was developed apart from Pfizer’s discontinued PF-06954522. This program lets Nxera control development fully. It shows their focus on unique chemistry and quick innovation. The pipeline has six more GPCR-targeted programs: three small molecule agonists (GIP, Apelin, Amylin), one GIP antagonist, and two long-acting programs that are undisclosed.
こちらもお読みください： Lantern Pharma completes LP-300 Lung cancer trial signup
Nxera uses its NxWave™ platform for drug design. This platform relies on special molecule libraries and protein screening tools. Together, they help find new drug candidates. The goal is to provide scalable treatments with few side effects. These treatments aim for long-term weight management. They help different patients, including seniors and those with other health problems.
ンクセラ・ファーマ is stepping up in the obesity treatments market, which is expected to exceed $100 billion each year. The company is also focusing on neurology, gastroenterology, and immunology.
日本語